Atlas FDA

Alere NMP22 BladderChek Test

FDA premarket approval P940035/S013 · decided 2016-09-08

Approval details

PMA number
P940035
Supplement
S013
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Alere NMP22 BladderChek Test
Generic name
System, test, tumor marker, for detection of bladder cancer
Applicant
Abbott Diagnostics Scarborough, Inc.
Date received
2016-08-16
Decision date
2016-09-08
Days to decision
23 days
Decision code
OK30
Product code
NAH
Advisory committee
Immunology
Expedited review
No
Location
Scarborough, ME
Statement
Additional vendor for the goat anti-mouse lgG antibody used in the manufacture of the Alere NMP22® BladderChek® Test procedural control line.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
BinaxNOW COVID-19 Ag Card (K250273)Abbott Diagnostics Scarborough, Inc.2025-06-13
BinaxNOW™ COVID-19 Antigen Self Test (K243518)Abbott Diagnostics Scarborough, Inc.2025-02-11
ID NOW Influenza A & B 2 (K232775)Abbott Diagnostics Scarborough, Inc.2023-10-10
ID NOW COVID-19 2.0 (K221925)Abbott Diagnostics Scarborough, Inc.2023-08-10
ID Now Instrument, ID Now Influenza A & B 2, ID NOW Strep A 2 (K220801)Abbott Diagnostics Scarborough, Inc.2022-06-24
ID NOW Influenza A & B 2 (K191534)Abbott Diagnostics Scarborough, Inc.2019-07-11